Between Hope and Harm: Who Decides?

Elena is a newborn baby, born at 36 weeks with confirmed Trisomy 18. The parents were aware of the prenatal diagnosis, and decided to take a conservative attitude by keeping the pregnancy. She has a large ventricular septal defect (VSD), esophageal atresia, and severe central apnea periods. Her diagnosis has been confirmed by post-natal genetic testing.

At this point, her situation is stabilized by parenteral nutrition, high-flow oxygen therapy and stimulation by the nursing staff during her periods of apnea. However, the frequency of the apnea episodes seems to be increasing.

Trisomy 18 (Edwards syndrome) is a severe genetic condition with a very low survival rate. Only about 5–10% of affected infants survive past their first year, with most dying within the first month due to heart or respiratory failures.

Elena’s parents have done extensive research online and are aware of cases where children with T18 live into their teens with significant medical support. They are demanding a "full intervention." This includes a surgical repair of her esophagus so she can eat, and later, open-heart surgery to fix the VSD. They argue that Elena's life has intrinsic value and that "disability does not equal a death sentence.”

The pediatric surgeons are refusing to operate. They argue that surgery is “physiologically futile”. Even if they fix the esophagus, Elena's underlying chromosomal condition means she will still have profound intellectual disability, frequent seizures, and a high likelihood of dying before her first birthday despite the pain of recovery from surgery.

As the Neonatologist, you are caught between the parents' "Right to Choose" and the medical team's "Right to Refuse" what they consider to be a non-beneficial, painful procedure.

At what point does "doing everything" become "doing harm"?

Private Genes, Public Consequences

You are a lead researcher running a large-scale genomic study on Early-Onset Alzheimer’s. You have recruited 500 participants for full-genome sequencing to find new biomarkers. One of your participants is Claire, a 28-year-old woman who joined the study because her grandmother had Alzheimer’s.

While reviewing Claire's genomic data for Alzheimer's markers, the laboratory flags a "secondary finding." Claire has an expanded CAG repeat (42 repeats) in her HTT gene.

This is the definitive genetic marker for Huntington’s Disease. This amount of repeats is associated with a complete penetrance, which means Claire is statistically 100% certain to develop the progressive, fatal neurodegenerative disorder, likely in her 40s or 50s.

When Claire signed the consent form for the Alzheimer's study, she checked a box that said: "I wish to be informed only of findings related to Alzheimer’s Disease. I do not wish to receive incidental findings about other incurable conditions."

Claire has an identical twin sister, Elena, who is currently seven months pregnant. If Claire has the gene, her twin Elena also has it with 100% certainty, and her unborn child has a 50% chance of inheriting it.

As a researcher, you know that while HD is incurable, there are now experimental gene-silencing trials (ASOs) that require participants to be pre-symptomatic. If you respect Claire’s wish not to know, you are effectively denying her, her sister, and her child the chance to join a trial that could save their lives.

Does a person's "Right to Ignorance" disappear if their ignorance actively harms others (their twin or child)? Does Claire "own" this data? Or is genetic data "communal property" belonging to her twin sister as well?